The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.522
Bid: 1.50
Ask: 1.58
Change: 0.015 (0.98%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.47
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor presentations

26 Sep 2017 07:00

RNS Number : 7722R
Silver Falcon PLC
26 September 2017
 

Silver Falcon Plc

(to become Hemogenyx Pharmaceuticals Plc)

 

Investor presentations

 

Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited ("Hemogenyx"), announces that it will be holding a series of meetings with investors regarding the opportunity presented to shareholders by the proposed acquisition of Hemogenyx LLC ("Hemogenyx").

 

The presentation will be led by Chief Executive Officer & Co-Founder of Hemogenyx, Dr Vladislav Sandler, with other Proposed Directors available for discussions after the formal presentation. The same presentation will be given at all events which are being held at different times to offer convenient options for those wishing to attend.

 

3 October 2017 - Lunchtime presentation hosted by Peterhouse Corporate Finance Limited

Time:

12.30pm - a sandwich lunch will be provided

Location:

3rd Floor New Liverpool House, 15 Eldon Street, London EC2M 7LD

 

3 October 2017 - Afternoon Presentation hosted by Shard Capital Partners LLP

Time:

5pm - the presentation will be followed by drinks and canapes

Location:

23rd Floor, 20 Fenchurch Street, London EC3M 3BY

 

4 October 2017 - Evening presentation hosted by Optiva Securities Limited

Time:

6pm - the presentation will be followed by drinks and canapes

Location:

Sartoria, 20 Savile Row, London W1S 3PR

 

 

For more information on the proposed acquisition see the Latest News section on: www.silverfalconplc.com

 

For a short video by Dr Sandler on Hemogenyx click here: www.brrmedia.co.uk/event/160159

 

If you would like to register for any of the investor presentations, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com ensuring you detail in your email which presentation you would like to attend.

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Peter Redmond, Director

Via Walbrook PR

 

 

Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 

 

 

 

Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar

 

 

 

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

 

 

Flowcomms IR

Mob: +44 (0)7891 627 441 or sasha@flowcomms.com

Sasha Sethi

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAFNSALLXEAF
Date   Source Headline
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.